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[1] and direct factor Xa inhibitor rivaroxaban 
[2] are two non-vitamin k oral anticoagulants 
(NOACs). They showed a better efficacy pro-
file compared to warfarin, as well as a greater 
simplicity of dosage, since they don’t require 
a periodic monitoring of the prothrombin 
time (expressed through the INR – Interna-
tional Normalized Ratio – index) [3,4].
IntroductIon
Oral anticoagulant treatment with either vita-
min K antagonist or non-vitamin K antagonist 
is essential for the prevention of stroke or sys-
temic embolism and all cause of mortality in 
patients with non-valvular atrial fibrillation. 
Direct thrombin inhibitor dabigatran etexi-
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AbstrAct
BACKGROUND: Dabigatran 150 mg BID (D150) and rivaroxaban 20 mg (R20) are indicated for the prevention of throm-
boembolic events in patients with Non-Valvular Atrial Fibrillation (NVAF). Outcomes from observational study demon-
strated that D150 and R20 reduced the rate of thromboembolic events.
OBJECTIVE: This analysis estimated the budget impact of the use of D150 and R20 for the treatment of NAFV patients 
in Italy.
METHODS: A budget-impact model (BIM) was developed to estimate the direct costs up to 12 months from an Italian 
NHS perspective. The resource utilization (drugs and intracranial hemorrhage or major extracranial bleeding event) was 
derived from an observational study. Only direct medical costs were considered. Ex-factory prices and National Tariffs 
were considered to estimate the costs of drugs and medical resource used, respectively. The BIM showed the difference of 
expenditure and clinical events (intracranial hemorrhage or major extracranial bleeding) generated by the base case calcu-
lated for current prescription volumes (D150 30%, R20 100%), and for different prescription volume scenarios (D150 at 
70% and 100%). Key variables were tested in the sensitivity analysis.
RESULTS: D150 was associated with a medical cost offset driven by fewer intracranial hemorrhage and major extracranial 
bleeding event, these offset the incremental drug cost and results in an annual saving per patient treated (D150: € 1,052.78; 
R20: € 1,161.23). The present scenario determines an annual cost of € 262,543,583. The impact of total annual costs for the 
Italian NHS would be lower if D150 prescription volumes would be higher. The total cost is predicted to decrease by 3.8% 
if the D150 prescription increase to 70% and it is predicted to decrease by 6.7% if the D150 prescription increase to 100%.
CONCLUSION: The use of D150, as an alternative to R20 to prevent events in patients with NVAF, could represent a cost-
saving option for the Italian NHS. 
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by following the Guidelines of the Interna-
tional Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) [7,8].
assumptions and input data
Clinical Data
The clinical data used for the comparison 
between dabigatran and rivaroxaban derive 
from the results of the retrospective obser-
vational analysis conducted by Graham and 
colleagues [9]. This analysis was performed 
with the aim to compare the rates of risk for 
thromboembolic stroke, intracranial hemor-
rhage, major extracranial bleeding (including 
gastrointestinal bleeding) and mortality for 
NVAF patients in prevention treatment with 
dabigatran 150 mg (BID) or with rivaroxaban 
20 mg. Between November 2011 and June 
2014, the analysis collected the data from 
118,891 NVAF patients (Medicare) aged ≥ 
65, of which 52,240 being treated with dabi-
gatran and 66,651 with rivaroxaban. Com-
pared to dabigatran, the use of rivaroxaban 
resulted in a non-significant reduction in 
thromboembolic stroke (HR 95% CI: 0.80; p 
= 0.7) and a significant increase in the risk for 
intracranial hemorrhage (HR 95% CI: 1.58; 
p = 0.002) and major extracranial bleeding 
(HR 95% CI: 1.47; p < 0.001), including gas-
trointestinal bleeding (HR 95% CI: 1.39; p < 
0.001).
From the study by Graham and colleagues, 
this analysis considered the efficacy data re-
lated to i) intracranial hemorrhages and ii) 
major extracranial bleeding; that is, the only 
events for which a statistically significant dif-
ference between the two pharmacological op-
tions considered here were identified [9].
Population
The number of patients was estimated start-
ing from the population resident in Italy on 1st 
January 2016 [10]. By applying a 2% preva-
lence rate [11], the population with AF was 
then calculated. From this, through market 
surveys and IMS data [12,13], it was pos-
sible to stratify the population to determine 
the number of NAVF patients treated with 
dabigatran 150 mg and rivaroxaban 20 mg. 
Such selection was made so that the popu-
lation subject of the BIM was homogenous 
to that considered in the study of Graham 
and colleagues [9], on which this analysis 
is based. This choice, however, has in actual 
fact excluded from the analysis the low doses 
of dabigatran (110 mg), rivaroxaban (15 mg) 
and two other NOACs (apixaban and edoxa-
ban) with indication for the prevention treat-
ment of NVAF patients. Table I shows in de-
tail the flow of patients.
Figure 1. Budget Impact model structure
AF = atrial fibrillation
NVAF patients treated with rivaroxaban 20 
mg daily or warfarin [4]. Also in this case, 
the primary efficacy endpoint was the inci-
dence of the events stroke or systemic embo-
lism, while the primary safety endpoint was 
constituted by major or clinically relevant 
minor bleeding. In the Per-Protocol analy-
sis, stroke or systemic embolism occurred 
in 188 patients receiving rivaroxaban (1.7% 
per year) and in 241 patients receiving war-
farin (2.2% per year) (Hazard Ratio – HR: 
0.79; 95% CI: 0.66-0.96; p < 0.001 non-
inferiority) [4]. In the analysis referred to 
the Intention-To-Treat population (which in-
cluded all events, from randomization to the 
completion of the study, regardless of how 
correctly patients had assumed the compara-
tor drugs), a substantial equality between ri-
varoxaban and warfarin in the prevention of 
the primary efficacy endpoint was achieved 
(HR: 0.88; 95% CI: 0.74-1.03; p = 0.12) [4]. 
However, mortality from all causes (4.5% 
and 4.9% per year, respectively; HR: 0.92; 
95% CI: 0.82-1.03; p = 0.15) and the primary 
safety endpoint (14.9% and 14.5% per year, 
respectively; HR: 1.03; 95% CI: 0.96-1.11; 
p = 0.44) did not show statistically signifi-
cant differences between the two treatment 
groups [4].
Since the results of a recent economic evalu-
ation conducted at national level suggest the 
cost-effectiveness of dabigatran and rivarox-
aban compared with warfarin in the preven-
tion treatment of NVAF patients [5], it seemed 
appropriate to assess the financial impact on 
the National Health Service (NHS), through 
a Budget Impact Analysis (BIA) aimed at 
estimating the sustainability. As a secondary 
objective, the BIA estimated the economic 
impact due to the use of idarucizumab in pa-
tients treated with dabigatran. Idarucizumab, 
in fact, is a monoclonal antibody used in the 
cases of emergency/urgency in which a rapid 
and specific inactivation of the anticoagulant 
effect of dabigatran is required [6].
Methods
The BIA was conducted from the Italian 
NHS perspective. Direct healthcare con-
sumption considered in the Budget Impact 
Model (BIM) describe, for NVAF patients, 
the cost of treatment with the two NOACs 
and the management of potential associated 
events, such as thromboembolic stroke, in-
tracranial hemorrhage or major extracranial 
bleeding. The analysis did not consider other 
direct medical costs, nor indirect costs. The 
time horizon covered by the model is 1 year. 
The BIM structure is illustrated schemati-
cally in Figure 1. This BIA was carried out 
In the RE-LY study, 18,113 patients with 
Non-Valvular Atrial Fibrillation (NVAF) 
were followed for two years, with the aim 
of comparing dabigatran 150 mg BID (bis in 
die) and 110 mg BID vs warfarin [3]. The in-
cidence of the events stroke or systemic em-
bolism formed the primary efficacy endpoint 
investigated by the study, while the presence 
of major bleeding was the primary safety 
endpoint. In the comparison with warfarin, 
dabigatran 150 mg significantly reduced the 
primary efficacy endpoint (Relative Risk 
– RR: 0.66; 95% CI: 0.53-0.82; p < 0.001), 
while the improvement associated with dabi-
gatran 110 mg (RR: 0.91; 95% CI: 0.74-1.11; 
p = 0.34) was not significant [3]. Dabigatran 
150 mg resulted in a borderline significant 
reduction in mortality (RR: 0.88; 95% CI: 
0.77-1.00; p = 0.051) [3]. Again compared 
to warfarin, the reduction in the incidence of 
major bleeding with dabigatran 110 mg was 
significant (RR dabigatran: 0.80; 95% CI: 
0.69-0.93; p = 0.003), while it was not for 
dabigatran 150 mg (RR: 0.93; 95% CI: 0.81-
1.07; p = 0.31) [3].
The ROCKET-AF study observed – dur-
ing a 19-month (mean) follow-up – 14,264 
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Drugs
In accordance with the time frame of one 
year, to which the risk rates estimated by the 
study of Graham and colleagues [9] are re-
lated, an administration period of 12 months 
was assumed for dabigatran and rivaroxaban, 
at an average daily dose of 150 mg BID (two 
150 mg capsules) and 20 mg (one 20 mg tab-
let), respectively [9].
In the base case, an average cost per treat-
ment day of € 2.23 for dabigatran and € 2.20 
for rivaroxaban was considered. These costs 
reflect the relevant ex-factory prices, net of 
the discounts required by law (-5%).
In the sensitivity analysis, two other scenar-
ios that, instead, reflect alternative price hy-
potheses for the two NOACs are presented. 
In addition to the discounts required by law 
(base case), further discounts – negotiated 
between the Regulatory Body (AIFA, the 
Italian Drug Agency) and the Pharmaceuti-
cal Companies – were considered. Unlike 
what happens for rivaroxaban, whose net 
price is generated by the application of a 
confidential discount, the additional dis-
count applied to dabigatran is composed of 
a fixed part (confidential discount for pub-
lic facilities) and a variable portion, linked 
to a price-volume agreement. According to 
the price-volume agreement, additional in-
cremental discounts are applied to the sale 
price to public structures, provided by the 
company in the form of payback, based on 
specific brackets of annual expenditure. In 
the first scenario, a parity price condition for 
the two treatments was simulated [14,15]. In 
the second, based on the most recent mar-
ket data, we tried to present a situation that 
would reflect the actual sales prices to public 
structures of the two NOACs, a scenario in 
which dabigatran would have a lower aver-
age cost per treatment day compared to riva-
roxaban [14,15].
n. source
Population resident in Italy on 1 January 2016 (n.) 60,795,612 [10]
Patients with AF (2%) 1,215,912 [11]
Patients with diagnosis of AF (84%) 1,021,366 [12]
Patients with diagnosis of AF in pharmacological 
treatment (92%)
939,657 [12]
Patients with diagnosis of AF in pharmacological 
treatment with NOACs (65%)
610,702 [12]
Patients in treatment with dabigatran (28.2%) 172,292 [13]
 • of whom in treatment with dabigatran 150 mg (40.8%) 70,295 [13]
Patients in treatment with rivaroxaban (42%) 256,495 [13]
 • of whom in treatment with rivaroxaban 20 mg (63.3%) 162,361 [13]
Tabella i. Population subject of the budget impact analysis
by following the Guidelines of the Interna-
tional Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) [7,8].
assumptions and input data
Clinical Data
The clinical data used for the comparison 
between dabigatran and rivaroxaban derive 
from the results of the retrospective obser-
vational analysis conducted by Graham and 
colleagues [9]. This analysis was performed 
with the aim to compare the rates of risk for 
thromboembolic stroke, intracranial hemor-
rhage, major extracranial bleeding (including 
gastrointestinal bleeding) and mortality for 
NVAF patients in prevention treatment with 
dabigatran 150 mg (BID) or with rivaroxaban 
20 mg. Between November 2011 and June 
2014, the analysis collected the data from 
118,891 NVAF patients (Medicare) aged ≥ 
65, of which 52,240 being treated with dabi-
gatran and 66,651 with rivaroxaban. Com-
pared to dabigatran, the use of rivaroxaban 
resulted in a non-significant reduction in 
thromboembolic stroke (HR 95% CI: 0.80; p 
= 0.7) and a significant increase in the risk for 
intracranial hemorrhage (HR 95% CI: 1.58; 
p = 0.002) and major extracranial bleeding 
(HR 95% CI: 1.47; p < 0.001), including gas-
trointestinal bleeding (HR 95% CI: 1.39; p < 
0.001).
From the study by Graham and colleagues, 
this analysis considered the efficacy data re-
lated to i) intracranial hemorrhages and ii) 
major extracranial bleeding; that is, the only 
events for which a statistically significant dif-
ference between the two pharmacological op-
tions considered here were identified [9].
Population
The number of patients was estimated start-
ing from the population resident in Italy on 1st 
January 2016 [10]. By applying a 2% preva-
lence rate [11], the population with AF was 
then calculated. From this, through market 
surveys and IMS data [12,13], it was pos-
sible to stratify the population to determine 
the number of NAVF patients treated with 
dabigatran 150 mg and rivaroxaban 20 mg. 
Such selection was made so that the popu-
lation subject of the BIM was homogenous 
to that considered in the study of Graham 
and colleagues [9], on which this analysis 
is based. This choice, however, has in actual 
fact excluded from the analysis the low doses 
of dabigatran (110 mg), rivaroxaban (15 mg) 
and two other NOACs (apixaban and edoxa-
ban) with indication for the prevention treat-
ment of NVAF patients. Table I shows in de-
tail the flow of patients.
Figure 1. Budget Impact model structure
AF = atrial fibrillation
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and emergency surgery reproduces what was 
calculated by the study of Belisari and col-
leagues [17], to which it is hereby referred 
to for details. Table II shows the overall cost 
per patient treated for each of the events con-
sidered in the hypothesis of use or non-use of 
idarucizumab.
Output data of the model
Budget Impact
In relation to the estimated number of treat-
able patients and the average annual cost 
associated therewith (pharmacological treat-
ment and management of events), the results 
of the BIM describe – during 12 months of 
analysis – the difference in the spending gen-
erated by the base case scenario with respect 
to two alternative scenarios, in which an in-
crease in the market shares of dabigatran 150 
mg (70% and 100%) is assumed. In addition 
to the expenditure data, the BIM provides for 
the same comparison also the variation in the 
number of events avoided (intracranial hem-
orrhage and major extracranial bleeding). 
Finally, as a secondary objective, the BIM 
presents the budget impact resulting from the 
use of idarucizumab in patients who were be-
ing treated with rivaroxaban 20 mg and who 
were then switched to dabigatran 150 mg.
results
Dabigatran vs rivaroxaban 
(base case)
Cost per patient treated
The patient treated with dabigatran 150 mg 
shows a reduction of 9.3% (€ -108,45) in the 
mean annual cost with regard to that associ-
ated with the patient being treated with riva-
roxaban 20 mg (Table III). The higher cost 
associated with the drug therapy (+1.4%; € 
10.95) is completely offset by the lower cost 
for the management of intracranial hemor-
rhage (-36.1%; € -30.54) and major extracra-
nial bleeding (-32.5%; € -88.87).
Expenditure borne by the NHS
The annual expenditure borne by the NHS, 
calculated on the current number of patients 
in treatment with the two therapeutic strate-
gies (dabigatran 150 mg: n. = 70,295; riva-
roxaban 20 mg: n. = 162,361) is equal to € 
262,543,628, of which € 74,004,954 generat-
ed by dabigatran 150 mg and € 188,538,628 
by rivaroxaban 20 mg (Figure 2). The num-
ber of events that would occur during the 
year would amount to 9,480, of which 1,211 
due to intracranial bleeding and 8,268 to ma-
jor extracranial bleeding (Figure 3).
Without idarucizumab With idarucizumab
gi iC OB es gi iC OB es
Idarucizumab 0.00 0.00 0.00 0.00 2,369.06 2,369.06 2,369.06 2,369.06
Diagnostic 
procedures
93.13 125.50 42.00 31.27 93.13 125.50 42.00 31.27
Treatments 3,112.30 3,769.07 3,140.74 1,098.29 606,47 773,16 624,90 66,36
Hospitalizations 8,800.17 8,800.17 8,800.17 1,855.25 6,766.39 8,800.17 6,766.39 10,859.48
Complications 247.69 274.81 247.69 732.96 12.90 12.90 12.90 281.99
ES 0.00 0.00 0.00 6,047.47 0.00 0.00 0.00 6,047.47
Total 12,253.29 12,969.55 12,230.60 19,765.23 9,847.95 12,080.79 9,815.25 19,655.63
Table ii. Mean cost per patient without and with idarucizumab
GI = gastrointestinal bleeding; IC = intracranial bleeding; OB = other type of bleeding; ES = emergency surgery
healthcare costs item






Drugs 813.95 803.00 10.95
Intracranial hemorrhage 54.17 84.71 -30.54
Major extracranial bleeding 184.65 273.52 -88.87
Total 1,052.78 1,161.23 ‑108,45
Table iii. Mean annual treatment cost
Figure 2. Annual expenditure borne by the NHS: base case scenario
Figure 3. Number of events: base case scenario
In addition to the base case – which had the 
purpose of providing a dimension of the cur-
rent annual expenditure generated by the use 
of the two NOACs (high doses) in the pre-
vention treatment of NVAF patients – two 
alternative scenarios are presented, in which 
the market share of dabigatran 150 mg covers 
70% or 100% of the patients treated. These 
alternative scenarios have the function to 
highlight the financial impact associated with 
a possible switch from rivaroxaban 20 mg to 
dabigatran 150 mg.
Impact of idarucizumab
The economic impact borne by the NHS and 
generated by idarucizumab was evaluated 
only for the additional number of patients 
who, with regard to the base case, would 
be treated in the alternative scenarios (dabi-
gatran 70% and 100%), following the switch 
from rivaroxaban 20 mg to dabigatran 150 
mg. The use of idarucizumab only for patients 
treated with dabigatran is in line with the cur-
rent therapeutic indications of the product 
[6]. Idarucizumab is in fact a specific inac-
tivator of dabigatran, in the cases where the 
rapid inactivation of its anticoagulant effects 
is necessary (emergency surgery/urgent pro-
cedures and life-threatening or uncontrolled 
bleeding). Most of the data used here to es-
timate the financial impact of idarucizumab 
refer to what was found by Belisari and col-
leagues [17]. Thanks to the results of the RE-
VERSE AD study [18] and the data collected 
through the CORE-CINECA database [19], it 
is estimated that 0.48% of patients receiving 
dabigatran may cope with an emergency sur-
gery (ES), while 1.05% can manifest uncon-
trolled or life-threatening bleeding events. 
The latter were divided into gastrointestinal 
bleeding (GI – 39.2%), intracranial bleeding 
(IC – 35.3%) and other type of bleeding (OB 
– 25.5%) [18]. The estimate of the health-
care resources needed for the management 
of uncontrolled or life-threatening bleeding 
Number and cost of the events
The BIM also provided an estimate of the 
average annual number of events associated 
with the two therapeutic strategies: intra-
cranial hemorrhage and major extracranial 
bleeding. These events were subsequently 
quantified using the costs reported in a recent 
Italian analysis, which assessed the cost-ef-
fectiveness of the non-vitamin k oral antico-
agulants in the prevention therapy in NVAF 
patients [16]. An average cost of € 14,500 
for the intracranial hemorrhage event (this 
amount takes into account the management 
of a moderate stroke – Barthel Index ≤ 14 
and ≥ 10 – and a possible disability) and € 
6,940.80 for the major extracranial bleeding 
event were considered. By means of the sen-
sitivity analysis, in addition to the base case, 
two other scenarios in which the event man-
agement cost was reduced first by 30% and 
then by 50% were evaluated.
Market Share
The market shares considered in the base 
case, equal to 30% and 70%, respectively, 
represent the percentage of current use of 
dabigatran 150 mg and rivaroxaban 20 mg 
in the prevention treatment of NVAF patients 
[12,13]. These percentages were calculated 
by relating the number of patients treated 
with dabigatran 150 mg (70,295) or rivaroxa-
ban 20 mg (162,361) to the total of patients 
considered in the BIM (232,656) (Table I).
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In correspondence of an increase in the mar-
ket share of dabigatran 150 mg that, com-
pared to the base case scenario, would lead 
to treat 70% or 100% of NVAF patients, 
there would be at the same time a signifi-
cant reduction in the expenditure borne by 
the NHS (dabigatran 150 mg 70% : -3.8% 
[€ -10,038,831]; dabigatran 150 mg 100%: 
-6.7% [€ -17,608,472]) and a slight increase 
in the number of the events avoided (dabi-
gatran 150 mg 70%: +1,380 events avoided; 
dabigatran 150 mg 100%: +2,241 events 
avoided) (Figure 4).
Sensitivity analysis
Table IV shows the main results of the sen-
sitivity analysis. The two scenarios that in-
and emergency surgery reproduces what was 
calculated by the study of Belisari and col-
leagues [17], to which it is hereby referred 
to for details. Table II shows the overall cost 
per patient treated for each of the events con-
sidered in the hypothesis of use or non-use of 
idarucizumab.
Output data of the model
Budget Impact
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erated by the base case scenario with respect 
to two alternative scenarios, in which an in-
crease in the market shares of dabigatran 150 
mg (70% and 100%) is assumed. In addition 
to the expenditure data, the BIM provides for 
the same comparison also the variation in the 
number of events avoided (intracranial hem-
orrhage and major extracranial bleeding). 
Finally, as a secondary objective, the BIM 
presents the budget impact resulting from the 
use of idarucizumab in patients who were be-
ing treated with rivaroxaban 20 mg and who 
were then switched to dabigatran 150 mg.
results
Dabigatran vs rivaroxaban 
(base case)
Cost per patient treated
The patient treated with dabigatran 150 mg 
shows a reduction of 9.3% (€ -108,45) in the 
mean annual cost with regard to that associ-
ated with the patient being treated with riva-
roxaban 20 mg (Table III). The higher cost 
associated with the drug therapy (+1.4%; € 
10.95) is completely offset by the lower cost 
for the management of intracranial hemor-
rhage (-36.1%; € -30.54) and major extracra-
nial bleeding (-32.5%; € -88.87).
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calculated on the current number of patients 
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by rivaroxaban 20 mg (Figure 2). The num-
ber of events that would occur during the 
year would amount to 9,480, of which 1,211 
due to intracranial bleeding and 8,268 to ma-
jor extracranial bleeding (Figure 3).
Without idarucizumab With idarucizumab
gi iC OB es gi iC OB es
Idarucizumab 0.00 0.00 0.00 0.00 2,369.06 2,369.06 2,369.06 2,369.06
Diagnostic 
procedures
93.13 125.50 42.00 31.27 93.13 125.50 42.00 31.27
Treatments 3,112.30 3,769.07 3,140.74 1,098.29 606,47 773,16 624,90 66,36
Hospitalizations 8,800.17 8,800.17 8,800.17 1,855.25 6,766.39 8,800.17 6,766.39 10,859.48
Complications 247.69 274.81 247.69 732.96 12.90 12.90 12.90 281.99
ES 0.00 0.00 0.00 6,047.47 0.00 0.00 0.00 6,047.47
Total 12,253.29 12,969.55 12,230.60 19,765.23 9,847.95 12,080.79 9,815.25 19,655.63
Table ii. Mean cost per patient without and with idarucizumab
GI = gastrointestinal bleeding; IC = intracranial bleeding; OB = other type of bleeding; ES = emergency surgery
healthcare costs item






Drugs 813.95 803.00 10.95
Intracranial hemorrhage 54.17 84.71 -30.54
Major extracranial bleeding 184.65 273.52 -88.87
Total 1,052.78 1,161.23 ‑108,45
Table iii. Mean annual treatment cost
Figure 2. Annual expenditure borne by the NHS: base case scenario
Figure 3. Number of events: base case scenario
108 Farmeconomia. Health economics and therapeutic pathways 2017; 18(1)
Budget impact analysis of dabigatran compared with rivaroxaban in the prevention of the thromboembolic risk
and 100%) is assumed, no parameter deter-
mines any significant variations of the results 
vs the base case (never higher than 11%).
Finally, the situation in which all patients 
are treated with rivaroxaban 20 mg was also 
evaluated. The expenditure for the NHS 
would increase by 2.9% compared to the base 
case (€ 270,167,248 vs € 262,543,628), with 
an increase of 11.1% in the number of events 
(10,528 vs 9,480).
idarucizumab
In view of the increases in the number of pa-
tients treated with dabigatran 150 mg assumed 
 scenario Vs base case1 Vs dabigatran 150 mg 70%2 Vs dabigatran 150 mg 100%2
Base case (€) 262,543,583 252,504,752 244,935,111
 • Variation (€) -10,038,831 -17,608,472
 • Variation (%) -4.0 -7.2
Parity price (€) [14,15] 217,615,704 206,563,293 198,229,376
 • Variation (€) -44,927,879 -11,052,411 -19,386,328
 • Variation (%) -17.1% -5.4% -9.8%
Lower cost/die dabigatran (€) [14,15] 216,845,973 204,779,983 195,681,790
 • Variation (€) -45,697,610 -12,065,991 -21,164,183
 • Variation (%) -17.4 -5.9 -10.8
-30% event costs (€)3 240,058,309 233,335,201 228,265,735
 • Variation (€) -22,485,274 -6,723,108 -11,792,574
 • Variation (%) -8.6 -2.9 -5.2
-50% event costs (€)3 225,068,126 220,555,500 217,152,817
 • Variation (€) -37,475,457 -4,512,626 -7,915,309
 • Variation (%) -14.3 -2.0 -3.6
Table iV. Sensitivity analysis
1 Variations are calculated compared to the base case scenario
2 Variations are calculated compared to the alternative scenarios
3 Major extracranial bleeding and intracranial hemorrhage
volve the inclusion of additional discounts 
for dabigatran 150 mg (discount to public 
facilities and price-volume agreement) and 
rivaroxaban 20 mg (discount to public facili-
ties) result in a reduction in the expenditure 
of around 17%, compared to the base case. 
Compared to the base case, the 30% or 50% 
reduction in the costs considered to quantify 
intracranial hemorrhage and major extracra-
nial bleeding causes a variation in the 8.6-
14.3% range.
Considering instead the alternative scenarios, 
in which an increase in the number of pa-
tients treated with dabigatran 150 mg (70% 
Figure 4. Annual expenditure borne by the NHS: base case scenario vs increase in the market share of dabigatran 150 mg
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the objective of the analysis was the direct 
(head-to-head) comparison between the two 
molecules, the analysis focused on what was 
available in the literature. The two pivotal 
clinical trials were excluded because they 
had been conducted to estimate the efficacy 
and safety of dabigatran [3] or rivaroxaban 
in the alternative scenarios (scenario 70%: 
+92,564 patients; scenario 100%: +162,361 
patients) compared to the base case, 1,416 
(scenario 70%) and 2,484 (scenario 100%) 
events would occur in which idarucizumab 
could be administered to quickly inactivate 
the anticoagulant effects of dabigatran (emer-
gency surgery/urgent procedures and life-
threatening or uncontrolled bleeding) (Table 
V). The use of idarucizumab would result in 
additional reductions in the treatment costs 
of € 1,868,758 and € 3.277,870, respectively 
(Table V).
dIscussIon And conclusIons
With the aim of providing a realistic scenario 
of the expenditure incurred by the NHS for 
the management of NAVF patients treated 
with dabigatran 150 mg or rivaroxaban 20 
mg, the BIM did not only provide a finan-
cial estimate of the pharmacological costs 
alone, but – in a more extended perspective 
– also considered the costs associated with 
the management of intracranial hemorrhage 
and major extracranial bleeding, events for 
which a significant difference between the 
two NOACs was recorded [9]. With regard to 
the base case scenario, a greater use of dabi-
gatran 150 mg would lead to a reduction in 
both the healthcare expenditure borne by the 
NHS (dabigatran 150 mg 70%: -3.8%; dabi-
gatran 150 mg 100%: -6.7%) and the number 
of intracranial hemorrhage (dabigatran 150 
mg 70%: -16.1%; dabigatran 150 mg 100%: 
-28.2%) and major extracranial bleeding 
(dabigatran 150 mg 70%: -14.3%; dabigatran 
150 mg 100%: -25.1%).
The subsequent adoption of idarucizumab in 
the cases of additional patients treated with 
dabigatran, for whom the rapid inactivation 
of the anticoagulant effects becomes neces-
sary, would result in a further reduction in the 
overall cost of the management of the clinical 
events (gastrointestinal, intracranial, extra-
cranial bleeding and other type of bleeding) 
equal to about € 1.8 million for the scenario 
dabigatran 150 mg: 70% and € 3.3 million for 
the scenario dabigatran 150 mg: 100%.
The dual effect determined by the increase 
in market shares of dabigatran 150 mg and 
the use of idarucizumab would result in an 
overall reduction in the expenditure borne 
by the NHS of around € 12 million (dabiga-
tran 70%) or € 21 million (dabigatran 100%) 
(Figure 5).
As is the case whenever it is necessary to use 
a simulation model, the results should be read 
in light of some remarks/limitations. Perhaps 
the most critical aspect is the choice of the 
clinical data used to populate the BIM. Since 
 
Dabigatran 150 mg 
scenario
70% 100%
Increases in the number of patients treated with 
dabigatran 150 mg compared to rivaroxaban (n.)
92,564 162,361
Total events/year (n.) 1,416 2,484
 • GI bleeding 381 669
 • Intracranial hemorrhage 343 602
 • Other type of bleeding 248 435
 • Emergency surgery 444 779
Costs (€) – scenario without idarucizumab (a)
 • GI bleeding 4,670,309 8,191,891
 • Intracranial hemorrhage 4,448,979 7,803,670
 • Other type of bleeding 3,030,078 5,314,867
 • Emergency surgery 8,781,869 15,403,716
Total 20,931,236 36,714,144
Costs (€) – scenario with idarucizumab (B)
 • GI bleeding 3,753,518 6,583,806
 • Intracranial hemorrhage 4,144,104 7,268,907
 • Other type of bleeding 2,431,686 4,265,265
 • Emergency surgery 8,733,170 15,318,296
Total 19,062,478 33,436,274
Difference scenario B ‑ a ‑1,868,758 ‑3,277,870
Table V. Economic impact of idarucizumab
GI = gastrointestinal
Figure 5. The dual effect determined by the increase in market shares of 
dabigatran and the use of idarucizumab
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Budget impact analysis of dabigatran compared with rivaroxaban in the prevention of the thromboembolic risk
those found by Larsen and colleagues [22] in 
the comparison between high doses of dabi-
gatran and rivaroxaban.
The sensitivity analysis tried to overcome, 
as far as possible, the limitations associated 
with other assumptions adopted, such as the 
price of the drugs or the cost associated with 
the management of intracranial hemorrhage 
and major extracranial bleeding. All com-
parisons substantially confirmed the results 
of the base case.
A recent study [25] assessed the cost-effec-
tiveness of dabigatran 150 mg BID versus 
rivaroxaban 20 mg QD for the treatment of 
patients with NVAF; the assessment was con-
ducted using clinical events based on a US re-
al-world evidence study by Graham et al. [9]. 
The same real-word data set was considered 
in our analysis. Patients on dabigatran were 
found to experience fewer bleeding events 
than patients on rivaroxaban. This lower in-
cidence in bleeding events led to lower costs 
among dabigatran which in turn was the key 
driver in the US study conclusion that dabi-
gatran was dominant over rivaroxaban in the 
US Medicare setting.
In conclusion, we believe that this analysis 
presents a reliable scenario – deriving from 
the use of dabigatran 150 mg and rivaroxaban 
20 mg in the treatment of NAVF patients in 
Italy – of how a larger prescription of dabi-
gatran 150 mg may result in a lower cost for 
the NHS. Since this analysis is one of the first 
attempts, it would be desirable, in the near fu-
ture, to be able to confirm this result against 
what will be evidenced by the clinical prac-
tice. Data obtained from Italian registers will 
in fact be able to definitively validate the anal-
yses deriving from the impact budget models.
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[4] vs. warfarin alone. Also the results of 
subsequent indirect comparison studies were 
not considered suitable, since they had been 
conducted on non-homogeneous populations 
and therefore, in actual fact, were not com-
parable [20,21]. From the clinical studies, 
research was then directed towards real life 
observational analyses. Four large retrospec-
tive observational analyses were therefore 
identified, three conducted in Europe [22-24] 
and one in the United States [9]. The three 
European analyses, all carried out on Dan-
ish registers, concern approximately 140,000 
patients diagnosed with NVAF in treatment 
with dabigatran (150 mg/110 mg), rivaroxa-
ban (15 mg/20 mg), apixaban (2.5 mg/5 mg) 
or warfarin. Despite the fact that they pres-
ent an overall better efficacy profile (mor-
tality rate, bleeding, or major bleeding) for 
dabigatran compared with rivaroxaban, in 
our view these analyses are characterized by 
a basic limitation of the study design, which 
in fact precluded their choice: clinical out-
comes are always calculated with respect to 
warfarin, and not between NOACs [22-24]. 
Unlike the observational analysis of Graham 
and colleagues, conducted on approximately 
120,000 patients enrolled in the Medicare 
program, it is the only one to have been con-
ducted with the objective to compare directly 
dabigatran 150 mg with rivaroxaban 20 mg, 
highlighting, when present, any significant 
differences between the two treatment groups 
[9]. For this reason, our choice fell on the lat-
ter observational analysis [9]. The adoption 
of the results of the observational analysis 
by Graham and colleagues [9], as a clinical 
basis of this budget impact model, is not in 
turn exempt from some criticism, such as the 
exclusion of the low doses of dabigatran (110 
mg) and rivaroxaban (15 mg), the American 
patient case histories and the fact that it in-
cludes only patients aged over 65. As a partial 
justification of these limits, it is emphasized 
that the observational analysis of Graham 
and colleagues [9] reflects results similar to 
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